BioNTech has obtained exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets that target a wide range of human cancers
Advancing Development of Personalized Antibody-Drug Conjugate Therapies for Solid Tumors
Convergent Total Synthesis of (+)-Ineleganolide
Natural product with a highly oxidized framework and a central seven-membered ring
Mn-Catalyzed Allylation of Benzoates
Simple manganese catalyst for ortho-C–H allylations, which can be combined with a decarboxylation to access allylarenes
Triazole-Substituted Ethisterones as Anticancer Compounds
Single-step syntheses of derivatives with promising cytotoxic activities
Highly Strained Antiaromatic Metallacycle Isolated
Smallest angle of a metal vinylidene within a six-membered ring reported so far
Use of Artificial Intelligence in Drug Development
WACKER, CordenPharma, Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin train machine learning algorithm to make RNA drugs
Aerobic C–C Bond Cleavage of Tertiary Allylic Alcohols
Co-catalyzed hydrogen atom transfer process gives ketones
Ensuring Ethical Standards in Emerging Technologies
Bayer establishes Bioethics Council comprising of renowned international experts
Electrochemical Reduction of Diarylketones and Aryl Alkenes
Using acetonitrile as the main proton donor in a mixed-solvent electrochemical reduction system
Linear Nb–Ga–Nb Fragment in a Bismuth Cage
First compound with Nb–Ga and Nb–Bi bonds